摘要:
目的 观察国产尼美舒利对类风湿关节炎(RA)和骨性关节炎(OA)的疗效和安全性。方法 选取RA患者59例和OA患者44 例。po 尼美舒利片100 mg,bid;对照组po 布洛芬缓释胶囊300mg,bid.治疗时间为4wk.分别观察治疗前后临床指标和炎性实验指标的变化。结果 尼美舒利治疗RA4wk 后,疼痛程度、压痛关节数、关节压痛指数、关节肿胀指数、握力、晨僵时间、血沉均显着改善。对RA的总有效率为83.3%.治疗OA4wk 后,膝关节活动痛、15m行走时间、日常活动能力及病人综合评估均有显着改善。对OA的总有效率为75.0% .其不良反应总发生率为19.2%, 以胃肠道反应为常见(9.6%).尼美舒利对RA和OA的疗效及不良反应的发生率与布洛芬相比均无显着性差异。结论 尼美舒利对RA和OA的疗效及不良反应的发生率均与布洛芬相当。
Abstract:
OBJECTIVE To test the efficacy and safety of nimesulide in patients with rheumatoid arthritis (RA) and osteoarthritis (OA) of knee. METHODS: 59 RA patients and 44 OA patients as defined by the American College of Rheumatology criteria were treated with oral nimesulide tablet 100 mg twice daily or ibuprofen 300 mg sustained release capsule twice daily for four weeks. RESULTS In patients with RA, VAS value, pain, Ritchie joint index, grip strength of hands, and morning stiffness improved significantly after treatment. In patients with OA of knee, overall pain, pain on movement, walking time, global efficacy and quality of life scores showed good levels of improvement compared with baseline. In 83.3% of RA patients and 75.0% of OA patients, nimesulide was effective. The frequent events reported were gastrointestinal disorders, occurring in 9.6% of nimesulide patients. The total incidence of adverse reactions was 19.2% in nimesulide patients. There were no significant differences in efficacy and safety between the treatment groups. CONCLUSION The efficacy and safety of nimesulide are equivalent to those of ibuprofen.
点击查看大图
下载:
